ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 001,80
-0,48%
Dow Jones
38 798,99
-0,22%
DAX
18 557,27
-0,48%
Brent Oil
79,395
0,00%
Bitcoin
69 387,84
0,08%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Autolus Therapeutics PLC (AUTL)

  7. Autolus Therapeutics PLC (AUTL) Actualités

AUTL

Autolus Therapeutics (AUTL)

Autolus Therapeutics PLC
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AUTL
DateHeureSourceTitreSymboleSociété
05/06/202422h35Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AUTLAutolus Therapeutics PLC
31/05/202414h00GlobeNewswire Inc.Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCONASDAQ:AUTLAutolus Therapeutics PLC
17/05/202422h39Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AUTLAutolus Therapeutics PLC
17/05/202413h00GlobeNewswire Inc.Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
14/05/202416h00GlobeNewswire Inc.Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) CongressNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202415h33Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:AUTLAutolus Therapeutics PLC
13/05/202413h00GlobeNewswire Inc.Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference CallNASDAQ:AUTLAutolus Therapeutics PLC
24/04/202416h00GlobeNewswire Inc.Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCONASDAQ:AUTLAutolus Therapeutics PLC
23/04/202413h00GlobeNewswire Inc.Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
02/04/202413h00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (B-ALLNASDAQ:AUTLAutolus Therapeutics PLC
01/04/202413h00GlobeNewswire Inc.Autolus Therapeutics Announces Changes to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
14/03/202412h00GlobeNewswire Inc.Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesNASDAQ:AUTLAutolus Therapeutics PLC
12/03/202412h00GlobeNewswire Inc.Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing siteNASDAQ:AUTLAutolus Therapeutics PLC
11/03/202412h00GlobeNewswire Inc.Autolus Therapeutics announces publication in Blood Cancer JournalNASDAQ:AUTLAutolus Therapeutics PLC
29/02/202413h00GlobeNewswire Inc.Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024NASDAQ:AUTLAutolus Therapeutics PLC
23/02/202423h28Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:AUTLAutolus Therapeutics PLC
22/02/202413h00GlobeNewswire Inc.Autolus Therapeutics announces publication in Nature Communications NASDAQ:AUTLAutolus Therapeutics PLC
21/02/202423h01Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:AUTLAutolus Therapeutics PLC
14/02/202414h37Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AUTLAutolus Therapeutics PLC
09/02/202423h15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:AUTLAutolus Therapeutics PLC
08/02/202413h00GlobeNewswire Inc.Autolus Announces Pricing of Underwritten OfferingNASDAQ:AUTLAutolus Therapeutics PLC
08/02/202411h45GlobeNewswire Inc.BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs  NASDAQ:AUTLAutolus Therapeutics PLC
08/02/202404h00Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:AUTLAutolus Therapeutics PLC
23/01/202413h00GlobeNewswire Inc.Autolus Therapeutics announces publication in ACS Chemical BiologyNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202413h54Dow Jones NewsAutolus Therapeutics Gets BLA Acceptance for Obecabtagene AutoleucelNASDAQ:AUTLAutolus Therapeutics PLC
22/01/202413h00GlobeNewswire Inc.Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)NASDAQ:AUTLAutolus Therapeutics PLC
10/01/202413h00GlobeNewswire Inc.Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of DirectorsNASDAQ:AUTLAutolus Therapeutics PLC
10/12/202302h30GlobeNewswire Inc.Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023NASDAQ:AUTLAutolus Therapeutics PLC
28/11/202320h59Dow Jones NewsCabaletta Bio Down as FDA Looks Into Issues With Several Companies' Approved CAR T DrugsNASDAQ:AUTLAutolus Therapeutics PLC
27/11/202313h54Dow Jones NewsAutolus Seeks FDA OK of Obe-Cel in Adult B-Cell Acute Lymphoblastic LeukemiaNASDAQ:AUTLAutolus Therapeutics PLC
 Showing the most relevant articles for your search:NASDAQ:AUTL

Dernières Valeurs Consultées

BIT
F18127
Vontobel Financial Produ...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés